Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q96LI5
UPID:
CNO6L_HUMAN
Alternative names:
Carbon catabolite repressor protein 4 homolog B
Alternative UPACC:
Q96LI5; Q9UF92
Background:
CCR4-NOT transcription complex subunit 6-like, also known as Carbon catabolite repressor protein 4 homolog B, plays a pivotal role in mRNA degradation and regulation. It exhibits 3'-5' poly(A) exoribonuclease activity, crucial for synthetic poly(A) RNA substrate processing. As a key component of the CCR4-NOT complex, it is involved in bulk mRNA degradation, miRNA-mediated repression, and translational repression, impacting cell proliferation and survival.
Therapeutic significance:
Understanding the role of CCR4-NOT transcription complex subunit 6-like could open doors to potential therapeutic strategies.